|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations显示文摘Non-alcoholic fatty liver disease(NAFLD)is the most common liver disease in the world.Presentation of the disease ranges from simple steatosis to non-alcoholic steatohepatitis(NASH).NAFLD is a hepatic manifestation of metabolic syndrome that includes central abdominal obesity along with other components.Up to80%of patients with NAFLD are obese,defined as a body mass index(BMI)>30 kg/m2.However,the distribution of fat tissue plays a greater role in insulin resistance than the BMI.The large amount of visceral adipose tissue(VAT)in morbidly obese(BMI>40 kg/m2)individuals contributes to a high prevalence of NAFLD.Free fatty acids derived from VAT tissue,as well as from dietary sources and de novo lipogenesis,are released to the portal venous system.Excess free fatty acids and chronic low-grade inflammation from VAT are considered to be two of the most important factors contributing to liver injury progression in NAFLD.In addition,secretion of adipokines from VAT as well as lipid accumulation in the liver further promotes inflammation through nuclear factor kappa B signaling pathways,which are also activated by free fatty acids,and contribute to insulin resistance.Most NAFLD patients are asymptomatic on clinical presentation,even though some may present with fatigue,dyspepsia,dull pain in the liver and hepatosplenomegaly.Treatment for NAFLD and NASH involves weight reduction through lifestyle modifications,anti-obesity medication and bariatric surgery.This article reviews the available information on the biochemical and metabolic phenotypes associated with obesity and fatty liver disease.The relative contribution of visceral and liver fat to insulin resistance is discussed,and recommendations for clinical evaluation of affected individuals is provided. | Sandra Milic Davorka Lulic Davor Stimac | 2014 | World Journal of Gastroenterology2014，20，28： | 52 |
| 2 | Transient elastography(Fibro Scan~?) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease- Where do we stand?显示文摘Non-alcoholic fatty liver disease(NAFLD) is the most common cause of chronic liver disease worldwide. Currently, the routinely used modalities are unable to adequately determine the levels of steatosis and fibrosis(laboratory tests and ultrasonography) or cannot be applied as a screening procedure(liver biopsy). Among the non-invasive tests, transient elastography(Fibro Scan?, TE) with controlled attenuation parameter(CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD, the factors associated with the diagnosis and NAFLD progression. The method is fast, reliable and reproducible, with good intra- and interobserver levels of agreement, thus allowing for population-wide screening and disease follow-up. The initial inability of the procedure to accurately determine fibrosis and steatosis in obese patients has been addressed with the development of the obese-specific XL probe. TE with CAP is a viable alternative to ultrasonography, both as an initial assessment and during follow-up of patients with NAFLD. Its ability to exclude patients with advanced fibrosis may be used to identify low-risk NAFLD patients in whom liver biopsy is not needed, therefore reducing the risk of complications and the financial costs. | Ivana Mikolasevic Lidija Orlic Neven Franjic Goran Hauser Davor Stimac Sandra Milic | 2016 | World Journal of Gastroenterology2016，22，32： | 33 |
| 3 | Nonalcoholic fatty liver disease-A multisystem disease?显示文摘Non-alcoholic fatty liver disease(NAFLD) is one of the most common comorbidities associated with overweight and metabolic syndrome(Met S). Importantly, NAFLD is one of its most dangerous complications because it can lead to severe liver pathologies, including fibrosis, cirrhosis and hepatic cellular carcinoma. Given the increasing worldwide prevalence of obesity, NAFLD has become the most common cause of chronic liver disease and therefore is a major global health problem. Currently, NAFLD is predominantly regarded as a hepatic manifestation of Met S. However, accumulating evidence indicates that the effects of NAFLD extend beyond the liver and are negatively associated with a range of chronic diseases, most notably cardiovascular disease(CVD), diabetes mellitus type 2(T2DM) and chronic kidney disease(CKD). It is becoming increasingly clear that these diseases are the result of the same underlying pathophysiological processes associated with Met S, such as insulin resistance, chronic systemic inflammation and dyslipidemia. As a result, they have been shown to be independent reciprocal risk factors. In addition, recent data have shown that NAFLD actively contributes to aggravation of the pathophysiology of CVD, T2 DM, and CKD, as well as several other pathologies. Thus, NAFLD is a direct cause of many chronic diseases associated with MetS, and better detection and treatment of fatty liver disease is therefore urgently needed. As non-invasive screening methods for liver disease become increasingly available, detection and treatment of NAFLD in patients with MetS should therefore be considered by both(sub-) specialists and primary care physicians. | Ivana Mikolasevic Sandra Milic Tamara Turk Wensveen Ivana Grgic Ivan Jakopcic Davor Stimac Felix Wensveen Lidija Orlic | 2016 | World Journal of Gastroenterology2016，22，43： | 32 |
| 4 | Metabolic aspects of adult patients with nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease(NAFLD) is a major cause of chronic liver disease and it encompasses a spectrum from simple steatosis to steatohepatitis, fibrosis, or cirrhosis. The mechanisms involved in the occurrence of NAFLD and its progression are probably due to a metabolic profile expressed within the context of a genetic predisposition and is associated with a higher energy intake. The metabolic syndrome(MS) is a cluster of metabolic alterations associated with an increased risk for the development of cardiovascular diseases and diabetes. NAFLD patients have more than one feature of the MS, and now they are considered the hepatic components of the MS. Several scientific advances in understanding the association between NAFLD and MS have identified insulin resistance(IR) as the key aspect in the pathophysiology of both diseases. In the multi parallel hits theory of NAFLD pathogenesis, IR was described to be central in the predisposition of hepatocytes to be susceptible to other multiple pathogenetic factors. The recent knowledge gained from these advances can be applied clinically in the prevention and management of NAFLD and its associated metabolic changes. The present review analyses the current literature and highlights the new evidence on the metabolic aspects in the adult patients with NAFLD. | Ludovico Abenavoli Natasa Milic Laura Di Renzo Tomislav Preveden Milica Medi?-Stojanoska Antonino De Lorenzo | 2016 | World Journal of Gastroenterology2016，22，31： | 17 |
| 5 | Nonalcoholic fatty liver disease and liver transplantation-Where do we stand?显示文摘Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis(NAFLD/NASH) is a challenging and multisystem disease that has a high socioeconomic impact. NAFLD/NASH is a main cause of macrovesicular steatosis and has multiple impacts on liver transplantation(LT), on patients on the waiting list for transplant, on posttransplant setting as well as on organ donors. Current data indicate new trends in the area of chronic liver disease. Due to the increased incidence of metabolic syndrome(Met S) and its components, NASH cirrhosis and hepatocellular carcinoma caused by NASH will soon become a major indication for LT. Furthermore, due to an increasing incidence of Met S and, consequently, NAFLD, there will be more steatotic donor livers and less high quality organs available for LT, in addition to a lack of available liver allografts. Patients who have NASH and are candidates for LT have multiple comorbidities and are unique LT candidates. Finally, we discuss long-term grafts and patient survival after LT, the recurrence of NASH and NASH appearing de novo after transplantation. In addition, we suggest topics and areas that require more research for improving the health care of this increasing patient population. | Ivana Mikolasevic Tajana Filipec-Kanizaj Maja Mijic Ivan Jakopcic Sandra Milic Irena Hrstic Nikola Sobocan Davor Stimac Patrizia Burra | 2018 | World Journal of Gastroenterology2018，24，14： | 14 |
| 6 | Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3显示文摘Hepatitis C virus(HCV) infection is a common chronic liver disease worldwide.Non-alcoholic fatty liver disease and insulin resistance(IR) are the major determinants of fibrosis progression and response to antiviral therapy.The pathogenetic link between IR and chronic HCV infection is complex,and is associated with HCV genotype.Liver steatosis is the most common in the patients infected with genotype 3 virus,possibly due to direct effects of genotype 3 viral proteins.To the contrary,hepatic steatosis in the patients infected with other genotypes is thought to be mostly due to the changes in host metabolism,involving IR.In HCV genotype 3,liver steatosis correlates with viral load,reverts after reaching the sustained virologic response and reoccurs in the relapsers.A therapeutic strategy to improve IR and liver steatosis and subsequently the response to antiviral treatment in these patients is warranted. | Ludovico Abenavoli Mario Masarone Valentina Peta Natasa Milic Nazarii Kobyliak Samir Rouabhia Marcello Persico | 2014 | World Journal of Gastroenterology2014，20，41： | 7 |
| 7 | Alimentary regimen in non-alcoholic fatty liver disease:Mediterranean diet显示文摘Non-alcoholic fatty liver disease(NAFLD)is the most common liver disease worldwide.The mechanisms of the underlying disease development and progression are awaiting clarification.Insulin resistance and obesity-related inflammation status,among other possible genetic,dietary,and lifestyle factors,are thought to play the key role.There is no consensus concerning the pharmacological treatment.However,the dietary nutritional management to achieve weight loss is an essential component of any treatment strategy.On the basis of its components,the literature reports on the effectiveness of the Mediterranean diet in reducing cardiovascular risk and in preventing major chronic diseases,including obesity and diabetes.New evidence supports the idea that the Mediterranean diet,associated with physical activity and cognitive behaviour therapy,may have an important role in the prevention and the treatment of NAFLD. | Ludovico Abenavoli Natasa Milic Valentina Peta Francesco Alfieri Antonino De Lorenzo Stefano Bellentani | 2014 | World Journal of Gastroenterology2014，20，45： | 7 |
| 8 | Adiponectin serum level in chronic hepatitis C infection and therapeutic profile显示文摘Hepatic steatosis is commonly seen in the patients with chronic hepatitis C virus(HCV) infection. HCV is closely associated with lipid metabolism,and viral steatosis is more common in genotype 3 infection owing to a direct cytopathic effect of HCV core protein. In non-genotype3 infection,hepatic steatosis is considered largely to be the result of the alterations in host metabolism; metabolic steatosis is primarily linked with HCV genotype 1. A d i p o s e t i s s u e s e c r e t e s d i f f e r e n t h o r m o n e s involved in glucose and lipid metabolisms. It has been demonstrated that adipocytokines are involved in the pathogenesis of non-alcoholic fatty liver disease,as the decreased plasma adiponectin levels,a soluble matrix protein expressed by adipoctyes and hepatocyte,are associated with liver steatosis. Various studies have shown that steatosis is strongly correlated negatively with adiponectin in the patients with HCV infection. The role of adiponectin in hepatitis C virus induced steatosis is still not completely understood,but the relationship between adiponectin low levels and liver steatosis is probably due to the ability of adiponectin to protect hepatocytes from triglyceride accumulation by increasing β-oxidation of free fatty acid and thus decreasing de novo free fatty acid production. | Valentina Peta Carlo Torti Natasa Milic Alfredo Foca Ludovico Abenavoli | 2015 | World Journal of Hepatology2015，7，1： | 4 |
| 9 | The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C显示文摘 | Ivana Lazarevic Jelena Djordjevic Maja Cupic Danijela Karalic Dragan Delic Neda Svirtlih Jasmina Simonovic Petar Svorcan Natasa Milic Tanja Jovanovic | 2013 | Journal of Clinical Virology2013，，： | 2 |
| 10 | Meta-analysis of stent thrombosis after drug-eluting stent implantation: 4-year follow-up显示文摘背景 Drug-eluting stents (DES ) 是在冠的动脉疾病的经皮的治疗使用的最普通的设备。最近,关于他们的安全侧面有一颗增加的担心,与赤裸的金属 stents (BMS ) 相比的特别地晚并且很迟了的 stent 血栓率。学习的目的是近来并且很晚比较报导发生在从有到四 years.Methods 的一个扩大后续时期的出版临床的研究的病人的 DES 和 BMS 的 stent 血栓搜索策略被开发识别在 BMS 和可得到的 DES 的晚或很迟了的血栓上报导的出版物通过 MEDLINE 和 Cochrane 图书馆数据库。二个独立评论家估价了合格研究并且提取了数据。机会比率(或) 为每结果被计算并且与 95% 信心间隔(CI ) 介绍了 .Results 十四使随机化控制试用,是使失明的至少单身者,被识别。近来在发生没有差别,在病人的很迟了的 stent 血栓与与 BMS 对待的病人相比与 DES 对待(迟了或 0.55, 95%Cl 0.23-1.31 和晚 / 很迟了的 OR=1.08, 95%CI 0.61-1.91 ).Conclusions 安全侧面 DES 以 stent 血栓类似于 BMS。我们没近来并且很晚发现增加的风险的证据为 DES 的血栓。 | Natasa M Milic Biljana J Parapid Miodrag C Ostojic Milan A Nedeljkovic Jelena M Marinkovic | 2010 | Chinese Medical Journal2010，，24： | 2 |
| 11 | Coiling of the left common carotid artery as a cause of transient iscbemic attacks显示文摘 | Milic DJ Jovanovic MM Zivic SS | 2007 | J Vasc Surg2007，45，2： | 1 |
| 12 | Influence of the prepa- ration procedure and chitosan type on physicochemical prop- erties and release behavior of alginate-chitosan microparti- cles显示文摘 | Cekic ND Milic JR Savic SD | 2009 | Drug Devlnd Pharm2009，35，9： | 1 |
| 13 | Prevention of pocket related complications With fibrin sealant in patients undergoing pacemaker implantation who are receiving anticoagulant treatment显示文摘 | Milic DJ Perisic ZD Zivic SS | 2005 | Europace2005，7，4： | 1 |
| 14 | High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels显示文摘 | Toncev G Milicic B Toncev S | 2002 | Clin Chem Lab Med2002，40，： | 1 |
| 15 | Context-based ensemble method for man energy expenditure estimation显示文摘 | Hristijan Gjoreski Bostjan Kaluza Matjaz Gams Radoje Milic Mitja Lustrek | 2015 | Applied Soft Computing2015，13，： | 1 |
| 16 | Importance of D-dimer testing in ambulatory detection of atypical and 'silent' phlebothrombosis显示文摘 | Jovanovic M Milic D Djindjic B | 2010 | Vojnosanit Pregl2010，67，7： | 1 |
| 17 | Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction 显示文摘 | Toncev G Milicic B Toncev S el al | 2002 | Eur J Neurol2002，9，： | 1 |
| 18 | The short term regulation of hepatic acetyl-CoA carboxylase during starvation and refeeding in the rat显示文摘 | Munday M R Milic M R TakharS | 1991 | Biochem J1991，280，： | 1 |
| 19 | Nonalcoholic fatty liver disease/steatobepatitis: epidemiology, pathogenesis, clinical presentation and treatment 显示文摘 | Milic S Stimac D | 2012 | Dig Dis2012，30，2： | 1 |
| 20 | Utilization of baker's yeast (Saccharomyces cerevisiae) for the production of yeast extract: effects of different enzymatic treatments on solid, protein and carbohydrate re- covery显示文摘 | MILIC T V RAKIN M MARINKOVIC S S | 2007 | J Serb Chem Soc2007，72，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员